DE602004006871D1 - Zusammensetzungen und verfahren, die multimere und oligomere lösliche fragmente des tweak-rezeptors betreffen - Google Patents

Zusammensetzungen und verfahren, die multimere und oligomere lösliche fragmente des tweak-rezeptors betreffen

Info

Publication number
DE602004006871D1
DE602004006871D1 DE602004006871T DE602004006871T DE602004006871D1 DE 602004006871 D1 DE602004006871 D1 DE 602004006871D1 DE 602004006871 T DE602004006871 T DE 602004006871T DE 602004006871 T DE602004006871 T DE 602004006871T DE 602004006871 D1 DE602004006871 D1 DE 602004006871D1
Authority
DE
Germany
Prior art keywords
tweak receptor
compositions
methods relating
soluble fragments
oligomer soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004006871T
Other languages
English (en)
Other versions
DE602004006871T2 (de
Inventor
Steven R Wiley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of DE602004006871D1 publication Critical patent/DE602004006871D1/de
Application granted granted Critical
Publication of DE602004006871T2 publication Critical patent/DE602004006871T2/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Radiation-Therapy Devices (AREA)
DE602004006871T 2003-07-24 2004-07-23 Zusammensetzungen und verfahren, die multimere und oligomere lösliche fragmente des tweak-rezeptors betreffen Active DE602004006871T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49003603P 2003-07-24 2003-07-24
US490036P 2003-07-24
PCT/US2004/023904 WO2005010045A1 (en) 2003-07-24 2004-07-23 Compositions and methods relating to multimeric and oligomeric soluble fragments of the tweak receptor

Publications (2)

Publication Number Publication Date
DE602004006871D1 true DE602004006871D1 (de) 2007-07-19
DE602004006871T2 DE602004006871T2 (de) 2008-02-07

Family

ID=34102961

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004006871T Active DE602004006871T2 (de) 2003-07-24 2004-07-23 Zusammensetzungen und verfahren, die multimere und oligomere lösliche fragmente des tweak-rezeptors betreffen

Country Status (9)

Country Link
US (1) US7482430B2 (de)
EP (1) EP1648936B1 (de)
JP (1) JP4823060B2 (de)
AT (1) ATE364050T1 (de)
AU (1) AU2004259355B2 (de)
CA (1) CA2531526C (de)
DE (1) DE602004006871T2 (de)
ES (1) ES2287773T3 (de)
WO (1) WO2005010045A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
US7001992B2 (en) * 1997-05-30 2006-02-21 Human Genome Sciences, Inc. Antibodies to secreted protein HEMCM42
AU2507700A (en) 1999-01-15 2000-08-01 Biogen, Inc. Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
US7208151B2 (en) * 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
US20060240004A1 (en) 2002-04-09 2006-10-26 Linda Burkly Methods for treating tweak-related conditions
US7939490B2 (en) * 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
WO2006089095A2 (en) * 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating neurological disorders
WO2006088890A2 (en) * 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating stroke
CN101160323A (zh) * 2005-04-15 2008-04-09 拉帕波特家族医学科学研究所 用于治疗mcp-1/ccr2相关疾病的分子及其使用方法
EP1885388B1 (de) 2005-05-10 2013-09-11 Biogen Idec MA Inc. Behandlung und beurteilung von entzündlichen erkrankungen
WO2006130429A2 (en) * 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
NZ564092A (en) * 2005-05-27 2010-05-28 Biogen Idec Inc TWEAK binding antibodies
WO2006138219A2 (en) * 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
EP2545938A1 (de) * 2007-08-03 2013-01-16 Abbott Biotherapeutics Corp. Therapeutische Verwendung von Anti-TWEAK-Rezeptorantikörpern
AU2009269141B2 (en) * 2008-06-30 2013-04-04 University Of Pennsylvania Fn14/TRAIL fusion proteins
CA2812057A1 (en) 2010-09-28 2012-04-05 Kahr Medical Ltd. Compositions and methods for treatment of hematological malignancies
RU2016100892A (ru) * 2013-06-14 2017-07-19 Байер Фарма Акциенгезельшафт Антитела против tweakr и их применение
US20210069319A1 (en) 2017-09-07 2021-03-11 University Of Oslo Vaccine molecules

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU678787B2 (en) 1992-10-23 1997-06-12 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5759546A (en) * 1994-02-04 1998-06-02 Weinberg; Andrew D. Treatment of CD4 T-cell mediated conditions
WO1998035061A2 (en) * 1997-02-12 1998-08-13 Abbott Laboratories Member of the tnf family useful for treatment and diagnosis of disease
WO2000006698A1 (en) 1998-07-30 2000-02-10 Human Genome Sciences, Inc. 98 human secreted proteins
US7001992B2 (en) * 1997-05-30 2006-02-21 Human Genome Sciences, Inc. Antibodies to secreted protein HEMCM42
EP1015477B1 (de) * 1997-05-30 2010-11-10 Human Genome Sciences, Inc. 32 Humane sekretierte Proteine
JP2002512524A (ja) 1997-06-03 2002-04-23 財団法人相模中央化学研究所 膜貫通ドメインを有するヒト蛋白質及びそれをコードするｄｎａ
WO1999019490A1 (en) 1997-10-10 1999-04-22 Genentech, Inc. Apo-3 ligand
EP1080194A2 (de) 1998-05-29 2001-03-07 Incyte Pharmaceuticals, Inc. Humane transmembranproteine
AU2507700A (en) 1999-01-15 2000-08-01 Biogen, Inc. Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
US6824773B2 (en) * 1999-12-20 2004-11-30 Immunex Corporation TWEAK receptor
US6727225B2 (en) * 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
WO2001085193A2 (en) 2000-05-08 2001-11-15 Biogen, Inc. Method for promoting neovascularization using a tweak agonist and an angiogenic factor
EP2260867A1 (de) 2000-09-14 2010-12-15 Biogen Idec MA Inc. TWEAK Rezeptoragoniste als antiangiogene Agenzien

Also Published As

Publication number Publication date
CA2531526A1 (en) 2005-02-03
US20050054047A1 (en) 2005-03-10
AU2004259355A1 (en) 2005-02-03
EP1648936A1 (de) 2006-04-26
ATE364050T1 (de) 2007-06-15
JP4823060B2 (ja) 2011-11-24
AU2004259355B2 (en) 2011-02-03
EP1648936B1 (de) 2007-06-06
CA2531526C (en) 2012-08-21
DE602004006871T2 (de) 2008-02-07
JP2007527224A (ja) 2007-09-27
ES2287773T3 (es) 2007-12-16
WO2005010045A1 (en) 2005-02-03
US7482430B2 (en) 2009-01-27

Similar Documents

Publication Publication Date Title
DE602004006871D1 (de) Zusammensetzungen und verfahren, die multimere und oligomere lösliche fragmente des tweak-rezeptors betreffen
MX2020009326A (es) Anticuerpos anti-claudina 18.2 y usos de los mismos.
NZ754051A (en) Novel antibodies and uses thereof
DE602004015810D1 (de) Substituierte isochinolinderivate und anwendungsverfahren
ATE362932T1 (de) Azaindolverbindungen als kinaseinhibitoren
ATE538650T1 (de) Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht
DE602004024900D1 (de) Substituierte 2,3-dihydro-1h-isoindol-1-one derivate und anwendungsverfahren
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
DE60229059D1 (de) Proteomimetische verbindungen und verfahren
UA86591C2 (ru) Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе
EA201100311A1 (ru) Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы
EP2185197A4 (de) Neue zellfaktorhaltige lösungszusammensetzungen
NO20063193L (no) Fusjonerte pyrrolokarbazoler og fremgangsmater for fremstilling derav
PH12020550986A1 (en) Heterocyclylamino-substituted triazoles as modulators of rho-associated protein kinase
NO20063196L (no) Nye fusjonerte pyrrolokarbazoler
MY153719A (en) Prokineticin 1 receptor antagonists
MXPA06003363A (es) Derivados de fenil-piperazina como moduladores de receptores muscarinicos.
WO2005042575A3 (en) Method for down-regulation of vegf
CY1114075T1 (el) Ενωσεις αλφα κετοαμιδιου ως αναστολεις πρωτεασης κυστεϊνης
EA201291346A1 (ru) Полиморфы osi-906
CY1113743T1 (el) Παραγωγα ισοκινολινονης ως ανταγωνιστες toy νκ3
WO2011116212A3 (en) Bone morphogenetic protein receptor binding agents and methods of their use
MX2020009522A (es) Anticuerpos anti-folato del receptor 1 y usos de los mismos.
ATE498022T1 (de) Universelle vervielfältigung von fragmentierter rns
IL165007A0 (en) Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis

Legal Events

Date Code Title Description
8364 No opposition during term of opposition